Estimate survival and disease progression in Alzheimer's disease based on stage, age, MMSE, comorbidities, and functional status. Includes stage duration and risk factor tables.
The Alzheimer's Life Expectancy Calculator estimates survival time and disease progression based on stage at diagnosis, current MMSE score, age, sex, comorbidities, mobility, and nutritional status — helping patients, families, and caregivers plan for the stages ahead.
Alzheimer's disease is the most common cause of dementia, affecting approximately 55 million people worldwide. The disease follows a generally predictable trajectory from mild cognitive impairment through severe dementia, though the pace varies widely between individuals. Median survival from diagnosis ranges from 3-12 years, heavily influenced by age at onset, stage at diagnosis, and overall health.
This calculator integrates multiple prognostic factors identified in large cohort studies to provide a personalized estimate. It projects MMSE decline trajectory, maps current function to disease stage, and provides data on modifiable and non-modifiable risk factors. While no prediction is exact, understanding the expected course helps families make informed decisions about care, finances, legal planning, and quality-of-life priorities.
Understanding disease trajectory helps families plan for care needs, financial arrangements, advance directives, and quality-of-life decisions at each stage. This calculator provides a structured framework for these difficult but essential conversations. This tool is designed for quick, accurate results without manual computation. Whether you are a student working through coursework, a professional verifying a result, or an educator preparing examples, accurate answers are always just a few keystrokes away.
Base median survival by stage: Preclinical ~10 yrs, Mild ~7 yrs, Moderate ~4.5 yrs, Moderately Severe ~3 yrs, Severe ~2 yrs Adjustments: Age <65 +3 yrs, 65-69 +1.5 yrs, ≥85 −1.5 yrs; Female +0.5 yrs; 2+ comorbidities −1 to −2 yrs; Wheelchair/bedbound −1 to −2 yrs; Poor nutrition/tube feeding −1 to −1.5 yrs MMSE Average Decline: ~3 pts/year (mild), ~4 pts/year (moderate), ~5 pts/year (severe)
Result: Estimated remaining: 6.5 years (range 4.6–8.5). Median from diagnosis: 7.5 years.
A 75-year-old female diagnosed 1 year ago with mild Alzheimer's (MMSE 22) and one comorbidity has an estimated median survival of 7.5 years from diagnosis. After 1 year, approximately 6.5 years remain. MMSE projected to decline to ~19 at 1 year and ~16 at 2 years.
Alzheimer's disease progresses through recognizable stages, from preclinical changes (detectable only on biomarkers) through mild cognitive impairment, mild dementia, moderate dementia, and finally severe dementia. The total disease course from biomarker onset to death spans 15-25 years, though the clinically symptomatic phase is typically 8-12 years.
**Mild stage:** Focus on legal/financial planning, advance directives, driving assessment, medication management support, and maintaining social engagement. **Moderate stage:** Implement in-home supervision, adult day programs, fall prevention, and begin evaluating long-term care options. **Severe stage:** Focus on comfort, dignity, pain management, infection prevention, and palliative/hospice referral when appropriate.
The landscape of Alzheimer's therapeutics is rapidly evolving. Anti-amyloid monoclonal antibodies (lecanemab, donanemab) represent the first disease-modifying therapies, though their clinical benefit is modest and they carry risks of amyloid-related imaging abnormalities (ARIA). Blood-based biomarkers are revolutionizing early diagnosis. Lifestyle interventions targeting cardiovascular risk factors, cognitive engagement, and physical exercise show meaningful prevention potential.
Population-level estimates are reasonably well-calibrated, but individual variation is enormous. Some patients decline rapidly (2-3 years), while others progress slowly (15+ years). The estimate provides a reference point, not a prediction.
Cholinesterase inhibitors (donepezil, rivastigmine) modestly slow cognitive decline (~1 MMSE point/year) but haven't definitively shown survival benefit. New anti-amyloid therapies (lecanemab, donanemab) show promise for slowing early-stage disease.
Earlier onset (before 65), APOE ε4 homozygosity, lower education, diabetes, cardiovascular disease, and behavioral symptoms (agitation, psychosis) are associated with faster decline. Use this as a practical reminder before finalizing the result.
The Mini-Mental State Exam ranges from 0-30. Normal: 26-30. Mild dementia: 20-25. Moderate: 10-19. Severe: <10. A decline of 3-4 points per year is typical for Alzheimer's.
Hospice criteria typically include: FAST stage 7c (unable to ambulate, dress, bathe; incontinent; <6 intelligible words per day), plus at least one complication in the past year (aspiration pneumonia, pyelonephritis, decubitus ulcers, or recurrent fever). Keep this note short and outcome-focused for reuse.
Early-onset (before 65) tends to progress faster and more aggressively, often with non-amnestic presentations. However, younger patients typically have fewer comorbidities, which can partially offset the faster progression.